Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Horowitz

Showing results (141-150 of 157) with videos related to

Pageof 16
Sort By:
Journal of the American College of Cardiology|April 1, 1985
Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery diseaseM J Kern, J D Horowitz, P Ganz, et al.
Journal of Cardiovascular Pharmacology|October 1, 1990
Determinants of acute hemodynamic and electrophysiologic effects of verapamil in humans: role of myocardial drug uptakeA C Powell, J D Horowitz, P J Kertes, et al.
European Heart Journal|August 9, 2001
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS studyJ G Cleland, K Thygesen, B F Uretsky, et al.
Circulation|May 1, 1986
Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart diseaseJ D Horowitz, M K Dynon, E Woodward, et al.
European Journal of Heart Failure|December 13, 2000
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study GroupM J Sculpher, L Poole, J Cleland, et al.
Journal of Cardiovascular Pharmacology|May 5, 2001
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failureG R Ellis, R A Anderson, Y Y Chirkov, et al.
Circulation|December 11, 1999
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study GroupM Packer, P A Poole-Wilson, P W Armstrong, et al.
Circulation|August 10, 2000
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trialB F Uretsky, K Thygesen, P W Armstrong, et al.
International Journal of Cardiology|August 17, 2016
New onset atrial fibrillation is associated with elevated galectin-3 levelsD Chen, N Procter, V Goh, et al.
The Annals of Thoracic Surgery|May 1, 1996
Prediction of outcome after revascularization in patients with poor left ventricular functionR K Chan, J Raman, K J Lee, et al.
Pageof 16

Showing results (141-150 of 157) with videos related to

Sort By:
Pageof 16
Journal of the American College of Cardiology|April 1, 1985
Attenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery diseaseM J Kern, J D Horowitz, P Ganz, et al.
Journal of Cardiovascular Pharmacology|October 1, 1990
Determinants of acute hemodynamic and electrophysiologic effects of verapamil in humans: role of myocardial drug uptakeA C Powell, J D Horowitz, P J Kertes, et al.
European Heart Journal|August 9, 2001
Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS studyJ G Cleland, K Thygesen, B F Uretsky, et al.
Circulation|May 1, 1986
Short-term myocardial uptake of lidocaine and mexiletine in patients with ischemic heart diseaseJ D Horowitz, M K Dynon, E Woodward, et al.
European Journal of Heart Failure|December 13, 2000
Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study GroupM J Sculpher, L Poole, J Cleland, et al.
Journal of Cardiovascular Pharmacology|May 5, 2001
Acute effects of vitamin C on platelet responsiveness to nitric oxide donors and endothelial function in patients with chronic heart failureG R Ellis, R A Anderson, Y Y Chirkov, et al.
Circulation|December 11, 1999
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study GroupM Packer, P A Poole-Wilson, P W Armstrong, et al.
Circulation|August 10, 2000
Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trialB F Uretsky, K Thygesen, P W Armstrong, et al.
International Journal of Cardiology|August 17, 2016
New onset atrial fibrillation is associated with elevated galectin-3 levelsD Chen, N Procter, V Goh, et al.
The Annals of Thoracic Surgery|May 1, 1996
Prediction of outcome after revascularization in patients with poor left ventricular functionR K Chan, J Raman, K J Lee, et al.
Pageof 16